HCA Warning, Leqembi Shift, PBM Scrutiny

Marcus"Welcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us."

Sara"And I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, especially the HCA news."

Marcus"Same here. We're looking at HCA's profit warning — what it signals for US healthcare access. Then the subcutaneous Leqembi approval — implications for HEOR. And the FTC settlement with CVS Caremark over insulin pricing."

Sara"That second one is interesting to me — the real-world adherence question with a new formulation is one the field hasn't fully worked out yet."

Marcus"Exactly. Let's get into it."

Marcus"HCA Healthcare issued a profit warning citing lower patient volumes and rising costs. This is significant because it's a leading indicator of access erosion in the US system. The company mentioned specific pressures on outpatient volumes and staffing costs, which are classic signs of system stress."

Sara"That's one read — but I'd frame it slightly differently. The profit warning is a symptom of broader financial pressures on hospital systems, which eventually cascade to patient access. What strikes me is the mention of lower volumes — that could mean patients are delaying care, which has long-term implications."

Marcus"That connects to something I keep coming back to: the sustainability of the US healthcare system. When major players like HCA signal trouble, it's not just about their bottom line. It's about whether the system can continue to support innovative therapies at scale."

Sara"Right, and from the payer side, that raises questions about budget impact. If hospitals are under pressure, how does that affect their ability to cover high-cost drugs? It's a feedback loop that HEOR teams need to model."

Marcus"Exactly. And this isn't isolated. We've seen similar signals from other hospital systems. The part that gives me pause is the rising costs — are we reaching a tipping point where the system can't absorb innovation without compromising access?"

Sara"I wonder if that's the full picture though. HCA also mentioned changes in payer contracts and reimbursement rates. That's a direct negotiation issue, which might be more about policy than system sustainability."

Marcus"That's fair. But the combination of volume decline and cost pressure is telling. For market access, this means we have to be more vigilant about demonstrating value in a system that's under stress. It's not just about the drug anymore; it's about the ecosystem."

Marcus"FDA approved the subcutaneous formulation of Leqembi for Alzheimer's. This is a big deal because intravenous infusions are a barrier for many patients. The new formulation could improve access, but it also introduces new evidence questions."

Sara"What's striking here is the potential for increased real-world adherence. Subcutaneous administration is easier, but we don't yet know if that translates to better outcomes in a real-world setting. That's a key evidence gap for HEOR."

Marcus"And from a commercial perspective, it's a win for Eisai. But the real question is value. The drug is expensive, and if adherence improves, does that justify the cost? We need to see long-term data on that."

Sara"That's one read — though I'd push back slightly on the commercial angle. For payers, the budget impact of a more accessible drug could be significant. If more patients get treated, the total spend might go up, even if per-patient costs are the same."

Marcus"That's a valid point. And it ties into the Alzheimer's disease-modifying therapy debate. We have to demonstrate that the incremental benefit of easier administration is worth the cost. The challenge is that the evidence base is still evolving."

Sara"The part that gives me pause is the lack of head-to-head data with the IV formulation. How do we model the comparative effectiveness? That's a methodological challenge HEOR teams will need to address."

Marcus"Exactly. This is one of those stories where innovation outpaces evidence generation. We need to think about pragmatic studies to fill the gaps."

Marcus"The FTC settled with CVS Caremark over insulin pricing practices. The settlement requires CVS to provide rebates and more transparency in its pharmacy benefit manager operations. This is significant because PBMs have been a black box in the insulin supply chain."

Sara"What strikes me about that is the potential for increased competition in insulin pricing. If PBMs are forced to pass savings to patients, it could lower out-of-pocket costs. But the devil is in the details of the rebate structure."

Marcus"And it's a direct challenge to PBM business models. The FTC is essentially saying that the way PBMs negotiate for insulin is anti-competitive. That could have ripple effects across other high-cost drugs."

Sara"Right, and from a payer perspective, this might lead to more predictable pricing for insulin. But I'm skeptical about the immediate impact on access. The settlement is with one PBM; we need to see if it sets a precedent."

Marcus"That's fair. But the fact that the FTC is stepping in signals a shift in how regulators view PBM practices. For HEOR, this means we have to be more transparent about the value chain in our value propositions."

Sara"The part that gives me pause is the potential for unintended consequences. If PBMs change their contracting, could that lead to formulary restrictions? We've seen that before with other drugs."

Marcus"That's a real risk. And it underscores the complexity of the US insulin market. This settlement is a step forward, but it's not a silver bullet for access."

Marcus"ICER expanded its early-phase scientific advice program to cover Phase I and II trials. This is a significant move because it aims to shape evidence generation much earlier in development. The goal is to reduce the risk of late-stage failures and misaligned evidence."

Sara"That's one read — though I'd frame it slightly differently. From a payer perspective, early engagement is crucial because it helps ensure that the evidence generated will be relevant to coverage decisions. It's about efficiency in the system."

Marcus"And it aligns with industry's need to de-risk development. If we can get payer input early, we can design trials that address their concerns. But the question is whether payers will engage meaningfully at that stage."

Sara"The part that gives me pause is the timing. Phase I and II are still very early, and the evidence is preliminary. How do payers provide meaningful advice when the data is so limited? It's a methodological challenge."

Marcus"That's a fair point. But ICER is trying to bridge that gap by focusing on study design endpoints and comparators. It's about setting the stage for later-stage trials. This could be a game-changer for rare diseases and oncology."

Sara"Right, and it connects to something I keep coming back to: the need for adaptive designs. If we can incorporate payer feedback early, we can make trials more flexible and responsive. That's a win for everyone."

Marcus"Exactly. This expansion signals a shift toward more collaborative evidence generation. It's not just about what the data says; it's about how we generate it."

Sara"A lot to think about today. I'll be watching how the HCA profit warning affects hospital negotiations for high-cost drugs."

Marcus"Same — and for me the thread running through today is the tension between innovation and system sustainability. Worth sitting with."

Sara"Thanks so much for listening — really glad you're here with us."

Marcus"We'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then."

Sara"Thanks for listening — see you tomorrow."

Marcus"Back tomorrow on Access Brief. Show notes at outcomes-analytica.no."